Viewing Study NCT02102633


Ignite Creation Date: 2025-12-25 @ 2:55 AM
Ignite Modification Date: 2026-03-01 @ 9:59 AM
Study NCT ID: NCT02102633
Status: COMPLETED
Last Update Posted: 2014-06-24
First Post: 2014-03-31
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Drug Interaction Study Between Bosutinib And Dabigatran
Sponsor: Pfizer
Organization:

Study Overview

Official Title: An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Oral Dose Of Bosutinib On The Pharmacokinetics Of Dabigatran Etexilate Mesylate Administered Orally To Healthy Subjects
Status: COMPLETED
Status Verified Date: 2014-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The study evaluates the effect of a single oral dose of bosutinib on the single dose pharmacokinetics of dabigatran, a p-glycoprotein substrate, in healthy subjects.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: